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ABSTRACT 
Advancing The Ability To Predict Cognitive Decline and Alzheimer’s Disease 
Based On Genetic Variants Beyond Amyloid-b and Tau   
 
By Naveen Rawat 
A growing amount of neurodegenerative R&D is focused on identifying genomic-
based explanations of AD that are beyond Amyloid-b and Tau. The proposed effort 
involves identifying some of the genomic variations, such as single nucleotide 
polymorphisms (SNPs), allele , chromosome, epigenetic contributors to MCI and 
AD that are beyond Aβ and Tau.  
The project involves building a prediction model based on a support vector machine 
(SVM) classifier that takes into account the genomic variations and epigenetic 
factors to predict the early stage of mild cognitive impairment (MCI) and Alzheimer 
disease (AD). To achieve this, picking up important feature sets which will be input 
to the machine learning model were identified using statistical model tests. The data 
used in this research were obtained from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) database / ADNI GO2 GWAS.  
Future work may involve increase in sample size analyzed from ADNI DB, explore 
and analyze potential secondary effects/medical-conditions such as other diseases 
that might have influenced the observed results and separate out MCI from AD and 
further explore predictions and results. 
Key Words: SNP Name, Allele1 - Plus, Allele2 - Plus, Chromosome, SNP  




Here the proposal is to advance the ability to predict cognitive decline and 
Alzheimer's disease based on genetic variants beyond Amyloid-b and Tau.  
I sincerely thank my advisor Dr. Wesley for giving me the opportunity to work and 
research in this field. Also I am greatly thankful to my committee members Dr. 
Newton and Dr. Andreopoulos for giving valuable feedback and suggestions during 
the tenure of this research. These esteemed computer science department faculty 
helped to shape up my research work with the most efficient, productive, and timely 
manner. With the aid of well established engineering tools, they guided me to narrow 
down on identifying some of the genomic variations, such as single nucleotide 
polymorphisms (SNPs), allele , chromosome, epigenetic contributors to MCI and 
AD. These genomic variations further were utilized in building prediction models 
for early onset of cognitive impairment detection.  
They mentored me throughout the project, on building the background with literature 
reviews, helping me to find the right approach and method for my experimentations, 
evaluating the experimentation results, which I got statistically as well as through 
my machine learning classifiers, and finally helped me to conclude on my project 
work.  
As a concluding remark, showing my utmost gratitude towards my committee 
members for guiding me around this experience, from start to till the end. 
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INTRODUCTION 
Alzheimer’s Disease (AD) is a type of dementia that is a neurovegetative disorder 
which impacted approximately 47 million or 0.6% of the global population in 2015 
(Rawtaer et al., 2020).  The number of AD diagnoses is projected to triple by 2050 
(Rawtaer et al., 2020).  More than 6 million Americans of any age have Alzheimer's 
(Lawlor, B. A. et al. ,1994). An anticipated 6.2 million Americans age sixty-five and 
older are residing with Alzheimer's dementia by 2021. Seventy- percentage are age 
seventy-five or older. One in nine human beings age sixty-five and older (11.3%) in 
America has Alzheimer's dementia (Dianxu Ren str al., 2020).   
 
The global costs of dementia in 2015 were estimated at $818 billion, a 35.4% 
increase compared with 2010. Up to 1 in 5 of the community-dwelling older adults 
aged 65 years and above suffer from mild cognitive impairment (MCI). Between 
10–15% of patients with MCI may develop dementia each year (Davis & Allen, 
2013). In addition, a recent meta-analysis indicated that about 45% of MCI patients 
maintained stable cognitive ability, whereas 28% progressed to AD and 15% 
returned to normal status without recurrence (Hu et al., 2017).  These are pandemic 
numbers and costs.  
 
AD is an irreversible, fast-spreading brain disease that slowly destroys memory, 
critical thinking capabilities and, eventually, the capacity to perform simple tasks 
that are needed to maintain independence. Most human beings with the disorder 
signs and symptoms first seem to be in their mid-60s (Lawlor, B. A. et al. ,1994). 
MCI causes a mild, however great and measurable, decline in cognitive abilities, 
together with memory and questioning skills. An individual with MCI is at an 
accelerated danger of growing Alzheimer's or any other dementia.[1] 
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In recent years, there has been significant efforts to develop biomarkers that can help 
with the early detection of AD and MCI [2]. These efforts can be roughly partitioned 
into approaches that are  (1) non-neuroimaging; (2) neuroimaging; (3) brain volume-
based;  and (4) genomic-epigenetic-based in nature. Example non-neuroimaging 
work to identify MCI and AD biomarkers typically involve evaluating metrics such 
as cerebrospinal fluid (CSF),  positron emission tomography (PET), and plasma, β-
amyloid, total tau (T-tau), and phosphorylated tau (Ptau) (Gao et al., 2021; Van et 
al., 2020).  Additional non-neuroimaging metrics include differentially methylated 
positions (DMPs) as novel blood-based biomarkers of AD (Vasanthakumar et al., 
2020).  Example neuroimaging work to identify MCI and AD biomarkers involve 
evaluating metrics such as an analysis of MRI images  (Stamate et al., 2020;  C.B. 
Hall et al., 2009; Patnode et al., 2020). Example brain volume-based work to identify 
AD and MCI biomarkers include the work of  Kotb’s group,  (Kotb et al., 2020).   
 
The results of work presented here lies within the category of genomic-epigenetic-
based approaches, and is beyond the well known Aβ and Tau based biomarkers 
which is the focus of groups such as Gao and Van (Gao et al., 2021; Van et al., 2020).  
Rather, related example work that falls within the category is that from Kim’s group 
(Kim et al., 2020). That is, excessive levels of Aβ and tau are not sufficient to 
diagnose or explain all instances of AD. Previous work has reported that between 
30% and 40% of normal individuals showed high levels of Aβ and tau (Bennett et 
al., 2006; Mintun et al., 2006).  
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In addition, despite high levels of tau showing a greater correlation with increased 
cognitive dysfunction than Aβ, taken together both have a relatively weak 
correlation with the degree of cognitive function. Furthermore, although tau 
accumulation showed a higher association with cognitive dysfunction than did Aβ, 
both pathogenic proteins demonstrated a weak to moderate association with the 
degree of cognitive function (Driscoll et al., 2011;  Giannakopoulos et al., 
2003).There must be, therefore, other pathogenic contributors, beyond  Aβ and tau, 
that can contribute to the onset and progression of AD.   
 
BACKGROUND 
The current diagnostic methods and symptoms related to AD are presented in many 
concluded research studies that clearly identifies Brain Amyloid-b (Aβ), in elevated 
amounts found in brains. As per them Amyloid-b is the main component of deposits 
that are found in the brains of patients with cognitive impairment (CI) and 
Alzheimer's disease (AD) (Dianxu Ren et al. 2020; Lianne M. Reus et al. 2020; Zhu, 
Xc. et al. 2020).  
However, relatively recent research has found that AD appears only if Aβ is followed 
by elevated levels of Tau (HangRai Kim et al. 2020). That is, AD does not appear in 
the absence of elevated Tau levels. (Rubinski et al. Alzheimer's Research & Therapy 
202)  
Genetic studies of Alzheimer's disease (AD) indicate that β-amyloid is important in 
the pathogenesis of the disease. However, amyloid-directed therapy usually does not 
slow down the development of patients with symptomatic diseases. (William J. Ray 
et al. Annu. Rev. Med. 2021. 72:15–28) 
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Despite many advances of the past two decades, the cause of many cognitive 
impairments (CI) and potent treatments remain puzzling to find. The hypothesis that 
amyloid- (A) peptides are the key causative agents of CI holds dominant among 
current researchers.  
Nevertheless, many existing research studies show evidence that A peptides are 
certainly not to be the only factor in AD etiology. A view of AD pathogenesis that 
encompasses both the amyloid-dependent and amyloid-independent mechanisms 
will help fill the gaps in knowledge and reconcile the findings that cannot be 
explained solely by the amyloid hypothesis. 
 
The search for purposeful CI and AD biomarkers remains wide and extensive. Many 
different academic as well as industry R&D sectors have and continue to make 
significant progress toward identifying CI and AD biomarkers.  
One of many technical gaps that remains, despite successful previous work to date, 
is the identification and characterization of additional genomic and epigenetic 
factors that are correlated with CI and AD.  
Having expanded knowledge about the genomic factors related to CI and AD is 
expected to be the basis of more robust biomarkers for these neurodegenerative 
diseases. Better and earlier detection of CI and AD can lead to earlier treatment, 
better outcomes, and lower costs associated with the diseases.  
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The research proposal here is to identify and characterize some of the 
genomic variations, such as single nucleotide polymorphisms (SNPs), 
allele, chromosome, epigenetic contributors to CI and AD that are beyond 
Aβ and Tau, which is present in most of the existing works.  
 
DATA 
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is an initiative of 
researchers who study data as they work to define the progression of Alzheimer’s 
disease (AD). ADNI researchers collect, validate and utilize data, including MRI 
and PET images, genetics, cognitive test and other biomarkers as predictors of the 
cognitive impairment. Study resources and data from the North American ADNI 
study are available through website login of  adni.loni.usc.edu. These data include 
Alzheimer’s disease patients, mild cognitive impairment subjects, and elderly 
controls.  
The datasets that are used for the project ADNI GO2_GWAS / Alzheimer's Disease 
Neuroimaging Initiative (Grand Opportunities) Genome-wide association study. 
The ADNI Genetics Core has released GWAS data for ADNI GO/2 
participants which is available from the download section.  Due to the 
large volume of data, the 750 individual subject files have been 
compressed into 15 zip files. In total around 735 subjects were analysed 
for this research project.  
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APPROACH AND METHOD 
 
To develop any predictive model, the first step is the identifying strong features set 
or input variables for the machine learning model with which reduces cost and time 
complexity, also better model performance can be achieved.  
Hence feature selection is an important criteria for success for any machine learning 
ML / SVM model. It can also be said as the process of reducing the number of input 
variables when developing a predictive model.   
Statistical-based feature selection methods, for example Chi-Square and correlation 
analysis involve evaluating the relationship between each input variable and the 
output or the response variable using statistics and selecting those features that have 
the strongest relationship with the response variable. These Statistical-based 
methods are standard industry based practices  and are fast and effective, also here 
the adoption of these mentioned statistical methods were governed by choice of the 
data sets used ADNI GO2 GWAS for both the input and response variables. As 
explained above, the Chi-Square test of independence and collreation test were used 
to decide if there's a considerable relationship among two  specific input / output 
variables. 
Furthermore, compare the frequency of each category of input variable with the type 
of the output variable. The statistical information is displayed in a contingency table, 
with each row representing the category of a variable and each column representing 
the category of the opposite variable. It can be said that researchers want to 
investigate the relationship between different category cognitive impairment Groups 
(CN 0, MCI 1, AD 2 ) versus genomic variations; Allele 1 & 2 Plus , chromosome, 
SNP and their portions in DNA sequence structure.  A contingency table is a form 
of table in a matrix layout that presents the frequency distribution of the variables. 
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Then the next step involves building a predictive model primarily on a support vector 
machine classifier that takes into account the input features identified here based on 
genomic and epigenetic factors to train for predicting the early stage of MCI. More 
details about how support vector machine classification is performed can be found 
in Appendix A.  
 
To generate training and test data sets for the SVM model the scikit Train-Test Split 
function is used. The train-test split function can be used to help buiuld classification 
or regression models which in turn and can be used as a basis for supervised learning 
algorithms. The procedure involves taking a dataset and dividing it into two subsets. 
In this project the 80: 20 ratio was used for train-test split evaluation. Common splits 
are 80% training data and 20% testing data, called simple hold-out splits, from 
sklearn.model_selection import train_test_split, X_train X_test y_train y_test = 
train_test_split (X, y, test_size=0.20, random_state=33) 
 
Figure 1. Train Test split function  
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EXPERIMENTAL METHOD 
As per initial steps for the experimental process the clean data sets are the must 
prerequisite as it is directly responsible for the machine learning model, SVM binary 
classifier.  
The pre-processing and cleaning stage for ADNA GWAS data files. Each file was 
in CSV format with a unique simple ID having around 75000 rows. Initially multiple 
attributes were considered; GC score, SNP index, SNP name,  Allele 1 plus, Allele 
2 plus, Chromosome, SNP position, GPA score, cluster separation, SNP , Allele 1 
plus Vs Allele 2 plus,etc. Statistical analysis of the feature set further narrowed down 
to particular Chromosome type, SNP type & Positions.  
['Chr'] == 4 &   ['SNP'] == 13 ['SNP'] == 42 
['Position'] == 21895517 or ['Position'] == 69033099 or  
['Position'] == 116283010 or ['Position'] == 189690332  
Some below substitutions were used here in the csv table as part of preprocessing 
datasets.       
0 = control, 1 = MCI, and 2 = AD   2.  
 For the nucleotides in the Allele columns, let A=1, C=2, G=3, T=4   and for the SNP 
column an A/T = 14, an A/C =12, A/G=13,..., T/A=41, T/C=42 ... and so forth.  
A Python-based support vector machine classified from scikit learn (CITE) was used 
for training and prediction of AD+MCI  from control (CN) and non-control MCI 
/AD subjects). Generated a dataset that is separable and includes classes – so, in 
short, an easy and binary dataset.  
Next created an SVM with a polynomial kernel to train a classifier, however not 
earlier than explaining the function of the kernel, also used C =1 and gamma to pass 
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a crucial part of SVMs. Finally post-processing helped in producing an accuracy 
confusion matrix as seen from high prediction model accuracy , lower counts on 
false positive , false negative results around the decision boundary of the model.   
 
When using SVM, necessarily using one of the kernels: linear, polynomial or 
RBF=Radial Base Function (also called Gaussian Kernel). The larger the gamma, 
the narrower the gaussian "bell" is. 
 
Split Train and Test data :: 80:20 ratio implemented by below function in code. 
x_train,x_test,y_train,y_test=train_test_split(X1,y,test_size=0.2)  
 
SVM with a polynomial kernel to train a classifier 
classifier = svm.SVC(kernel='poly', C=1, gamma=0.01, class_weight='balanced') 
Results will be verified by splitting the data-sets into training and test sets to get a 
more accurate assessment of SVM classifier's performance. Also SVM model binary 
outcome for predicting early onset of cognitive impairment will be compared with 
the actual ADNI sample dataset results to pick for any false positive and false 
negative based on confusion matrix.  
 
RESULTS  
In machine learning ML , functions are independent single variables or features that 
can be used as input to the system. In fact, when models make predictions, they use 
these attributes (features) to make predictions.  
The class label is a discrete attribute, and you want to predict its value based on the 
values of other attributes. In this case, a controlled normal group CN or mild 
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cognitive impairment MCI /AD are binary class names. The intent is to analyze a 
function to calculate whether a person with a specific attribute value will be a 
candidate for MCI / AD or not.  
Experimentation results were derived with the built SVM binary classifier. Having 
a polynomial kernel with C=1 and gamma=0.01, resulted in a prediction accuracy of 
78.32 % or higher. Allele, Chromosome, SNP and SNP positions features were 
identified as input to the binary ML model predicting either cognitive impairments 
versus none for a certain control group.  
How did you assess the quality and correctness of the obtained results? 
 
To assess the quality and correctness of the obtained results , a two pronged approach 
is taken. First from statistical analysis features were identified using statistical 
models Contingency table, Chi square test, Pearson correlation test. The data used 
in this research were obtained from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) database / ADNI GO2 GWAS. 
Next best of the features narrowed down from above statistical analysis were fed 
into a predictive model based on a support vector machine (SVM) classifier that 
takes into account the genomic variations and epigenetic factors to predict the early 
stage of MCI/AD.  
From these binary SVM classifiers an accuracy of around 78% were achieved to 
predict early stages of MCI / AD versus normal people.  
Below examples of features extracted from genomic variations were fed into inputs 
to the SVM classifier.   
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['Chr'] == T  
&    
['SNP'] == AG ['SNP'] == TC 
& 
['Position'] == 21895517 or ['Position'] == 69033099  
or  
['Position'] == 116283010 or ['Position'] == 189690332  
 
A small change of adding C and gamma value seems to be bumping Up accuracy 
considerably.  
classifier = svm.SVC(kernel='poly', C=1, gamma=0.01, class_weight='balanced') 
This comparatively higher accuracy for our experimental results. 
 
EXPERIMANTAL RESULTS 
As per observed experimental results statistical tools lead to better identification of 
feature sets used in machine learning models. Contingency table, Chi square test, 
correlation test, highlighted genomics variations with higher frequencies for 
example chromosome-type,  allele  or around SNP for a group. 
Results observed from Statistical tools / Chi-square test and Pearson correlation :  
  
 1- Here MCI group has a high number of nucleotides in the Allele type T.  
 >>> print(contingency Table)   
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 In statistics, a contingency table is a cross tabulation type of table in a matrix 
format that displays the frequency distribution between the variables.  Here it's 
providing a picture of the interrelation between two variables that is the strong 
relationship between MCI and Allele1 plus type G. 
  
 Allele1 - Plus     1    2     3     4 
 Group                                 
 0                475  380   452   943 
 1               1117  938  1255  2465 
 2                325  266   345   699 
 
 
2-      Similarly, the MCI  group can observe a high number of Chromosome 4 
genomic types.   
 Here as per contingency table it's providing a picture of the interrelation between 
two variables, that is a strong relationship between mild cognitive impairment 
MCI and Chromosome type 4 . 
 
>>> print(contingencyTable) 
Chr     2    3     4    12 
Group                      
0      149  300  1651  150 
1      385  770  4235  385 
2      107  216  1203  109 
 
 
3-    MCI group has observed a high number of A/G genomic types for single 
nucleotide polymorphisms SNP.    
 
 Here as per contingency table it's providing a picture of the interrelation between 
two variables, that is a strong relationship between mild cognitive impairment 
MCI and SNP 13 or A/G . 
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>>> print(contingencyTable) 
SNP     12    13    42   43 
Group                       
0      300  1049   749  152 
1      770  2694  1924  387 
2      218   758   543  116 
 
 The chi-square test of independence further can be used to examine these above 
stated relationships. Based on Chi-square statistics & p-value one can conclude that 
a relationship exists between the categorical variables; that is the results are 
significant or not.  
 
Here objectives involve identifying some of the genomic variations, such as single 
nucleotide polymorphisms (SNPs), allele , chromosome, epigenetic contributors to 
MCI and AD that are beyond that related to Aβ and Tau. These areas of interest were 
answered here with encouraging results showing positive prediction accuracy for 
selected genomic features and strong potential to expand into research scoping 
beyond Aβ and Tau. And can further expand into identifying more genomic 
variations for developmental prediction models based classifiers.   
 
CONCLUSION AND DISCUSSION 
The proposed effort involved identifying some of the genomic variations, such as 
single nucleotide polymorphisms (SNPs), allele , chromosome, epigenetic 
contributors to MCI and AD that are beyond that related to Aβ and Tau.  
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The project led to building a predictive model based on a support vector machine 
(SVM) classifier that takes into account the above mentioned genomic variations 
and epigenetic factors to predict the early stage of MCI/AD. Based on the results 
from the SVM binary classifier it is evident that using certain genetic variations can 
be used for predicting early onset of cognitive impairment diseases.  
The research strategy used here can be helpful to engineer better mechanisms to 
enhance classification models for early stage detection of cognitive impairments.  
 
FUTURE WORK 
Explore the genes the SNPs are associated with to see if there are metabolic 
pathways involved or epigenetic relationships with other known causes or factors 
related to AD/MCI. Secondly, increase sample size analyzed from ADNI DB. Next 
explore and analyze potential secondary effects/medical-conditions such as other 
diseases that might have influenced the observed results. Separate out MCI from AD 
















Fig 2 .Separable Data for SVM classifier   
The above figure depicts the use of a support vector machine (SVM) when data has 
exactly two classes that are in here, two subjects control group (CN) Vs cognitive 
impairment (MCI/AD). An SVM classifies data by finding the best hyperplane that 
separates all data points of one class from those of the other class. The best 
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hyperplane for an SVM means the one with the distinct margin between the two 
classes. Margin means the width of the slab parallel to the hyperplane that has no 
internal data points. 
As with any supervised learning model, first train a support vector machine, and then 
cross validate the classifier. Use the trained machine to predict new data. In addition, 
to obtain acceptable predictive accuracy, test various SVM kernel functions, and 
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